Abstract Purpose: To evaluate sunitinib activity and potential cellular and molecular correlates in gastrointestinal stromal tumor (GIST) patients after imatinib failure, in addition to assessing the safety and pharmacokinetics (PK) of different dose schedules. Experimental Design: In this open-label, dose-ranging, phase I/II study, 97 patients with metastatic imatinib-resistant/intolerant GIST received sunitinib at doses of 25, 50, or 75 mg/d on one of three schedules. Serial tumor imaging was done using computed tomography and [
receptor-α (PDGFRA; refs. 2, 3). In ∼10% of patients, no kinase mutations are detectable in either of these two genes, although uncontrolled KIT kinase activation has been noted even in the absence of mutation (2, 4) . The survival of metastatic GIST patients was dramatically improved by treatment with the KIT and PDGFRA inhibitor imatinib mesylate (Gleevec; refs. 5, 6) . However, imatinib resistance emerges due most commonly to evolution of secondary KIT or PDGFRA mutations (7) (8) (9) (10) . Therefore, systemic therapies are needed for GIST patients once imatinib resistance appears and for the small subset who are imatinib intolerant.
Sunitinib malate (SUTENT) is an oral, multitargeted tyrosine kinase inhibitor with potent activity against KIT, PDGFRs, vascular endothelial growth factor receptors (VEGFRs), and several other RTKs (11) (12) (13) (14) (15) . Sunitinib may exert antitumor activity in imatinib-resistant GIST by inhibiting imatinib-resistant RTK mutants and/or RTKs involved in tumor angiogenesis (including VEGFRs and PDGFRB). Here, we present the final analysis of safety, pharmacokinetics (PK), and clinical and biological activity of sunitinib in a phase I/II trial of GIST patients after imatinib failure due to resistance or intolerance, following earlier reports from this study (16, 17) . These results supported both the subsequent randomized, placebo-controlled, phase III study that confirmed the clinical benefit of sunitinib (18) and multinational approval of sunitinib in this patient population (19) .
Materials and Methods
Patients. Adults with histologically confirmed metastatic and/or unresectable GIST with documented imatinib failure due to resistance or intolerance were eligible for the study. Inclusion criteria included measurable disease, Eastern Cooperative Oncology Group performance status 0 to 2 (amended to 0 to 1), adequate nutritional and hematologic status, and adequate major organ function. Discontinuation of imatinib ≥2 wk before initiating sunitinib was required. The study was approved by the institutional review boards of the participating institutions; written informed consent was obtained from all patients.
Procedures. This was an open-label, single-arm, sequential cohort, dose-escalation phase I and early phase II trial to establish a phase II sunitinib dosing schedule based on safety, PK, and preliminary biological and clinical activity. Secondary objectives included doing [ 18 F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET), histologic review, assessments of KIT phosphorylation and tumor cell proliferation, and tumor kinase genotyping to explore possible correlations with clinical activity. The relationship between kinase genotype and sunitinib activity in this study has been reported elsewhere (20) .
Separate patient cohorts received sunitinib orally on one of three cyclical treatment schedules: Schedule 2/2 (2 wk on sunitinib, 2 wk off), Schedule 4/2 (4 wk on, 2 wk off), or Schedule 2/1 (2 wk on, 1 wk off ). Schedule 2/2 dosing started at 25, 50, or 75 mg/d; Schedules 4/2 and 2/1 started at 50 mg/d. Patients experiencing clinical benefit [complete response (CR), partial response (PR), or stable disease (SD) ≥6 mo] at study end were eligible for extended treatment in a treatment continuation study.
Patients underwent regular physical examinations and evaluations of performance status, body weight, complete blood counts, and serum biochemistry. Cardiac monitoring included serial weekly measurements of cardiac troponin (TnT and/or TnI) and total creatinine kinase, electrocardiograms, and determination of left ventricular ejection fraction (by electrocardiogram or multigated acquisition scan) in each cycle. Adverse events were graded according to National Cancer Institute Common Toxicity Criteria, version 2.0 (21) .
Tumor imaging and response assessments. Objective response was assessed by computed tomography (CT) or magnetic resonance imaging at baseline and the end of every even-numbered cycle. Disease status was assessed using Response Evaluation Criteria in Solid Tumors as CRs, PRs, SD, or progressive disease (PD; ref. Tumor metabolic response was examined by FDG-PET on an ECAT Exact HR+ tomograph (Siemens/CTI). Serial FDG-PET scans were done in a fasting state 1 h following i.v. administration of FDG (15) (16) (17) (18) (19) (20) at baseline, after the first 7 d of sunitinib dosing, at the end of cycle 1 dosing, and once during subsequent cycles.
Plasma drug concentrations. Plasma samples collected in K 3 EDTA were assayed to determinate concentrations of sunitinib and active metabolite SU12662 using a validated, sensitive, and specific liquid chromatographic tandem mass spectrophotometric method as previously described (23) .
Histologic and correlative science studies. Tumor biopsy samples were collected at baseline and (with patient consent) at other time points for conventional histologic review and immunoblotting/immunohistochemical studies.
For immunoblotting studies, protein lysates were prepared from snap-frozen core biopsies as described previously (24) . Protein concentrations were determined using the Bio-Rad Protein Assay (Bio-Rad Laboratories). Phosphorylated and total proteins were detected on immunoblots by enhanced chemiluminescence (Amersham), and chemiluminescence signals were captured and quantified using a FUJI LAS1000plus system with Science Lab 2001 ImageGauge 4.0 software (Fujifilm Medical Systems). Antibodies for immunoblotting analyses were polyclonal rabbit antibodies to phospho-KIT Y703 (Zymed Laboratories), polyclonal rabbit antibodies to phospho-AKT S473 (Cell Signaling), mouse monoclonal anti-p27 (clone 57; BD Transduction Laboratories), mouse monoclonal anti-cyclin A (clone 6E6; Novocastra), and polyclonal rabbit antibodies to total KIT (DAKO).
Immunohistochemical analysis of KIT was done using the rabbit polyclonal antibody A4502 (1:250; DAKO) and routine immunohistochemical methods without antigen retrieval (25) . Tumor cell proliferation was assessed by detection of Ki67 using the MIB-1 antibody (monoclonal; 1:200; pressure cooker antigen retrieval; Immunotech).
Tumor genotyping. Primary and secondary KIT mutations were determined using PCR analysis of genomic DNA obtained from tumor biopsies as described (20) .
Translational Relevance
Statistical analysis. All patients receiving at least one dose of sunitinib were included in these analyses. Descriptive statistics were used to summarize baseline characteristics, clinical responses, and adverse events. Time-to-event data were analyzed using Kaplan-Meier methods.
Results

Patients and treatment. Between March 2002 and December
2003, 97 patients were enrolled in the treatment cohorts described in Materials and Methods as shown in Table 1 . All patients had advanced GIST with bulky metastatic disease, including 94% with liver metastases. Patients had previously received imatinib at a median maximum dose of 600 mg/d.
Prior imatinib failure was due to resistance in 96% of patients and intolerance in the remaining 4%. Table 1 provides additional baseline characteristics.
All 97 study patients received at least one sunitinib dose. Of these, 36 (37%) completed treatment (and entered the treatment continuation protocol) and 61 (63%) discontinued treatment: 47 (48%) due to lack of efficacy, 8 (8%) to adverse events, and 6 (6%) to withdrawal of consent. As of March 2006, patients had started a median of six cycles of treatment (range, 0-43) and had been on sunitinib for a median of 4.4 months (range, 0.3-24), excluding off-treatment periods. Treatment was interrupted in 59 patients (61%), and the dose was reduced in 13 patients (13%).
The .0 months). In the overall study population, median progression-free survival was 7.8 months (95% confidence interval, 5.1-10.6 months).
With follow-up through March 2006, the number of patients obtaining clinical benefit increased to 52 (54%: 7 objective PRs, 45 durable SD). Median progression-free survival was 7.8 months (95% confidence interval, 5.1-10.4 months); median overall survival was 19.0 months (95% confidence interval, 12.9-21.5 months).
Sixty-seven patients (69%) had FDG-PET imaging data available from baseline and at least one postbaseline scan. Of 60 patients with data available on day 7 of cycle 1, FDG-PET revealed partial metabolic responses (PMR) to sunitinib in 43 patients (72%; Schedule 2/1, 5 of 7; Schedule 2/2, 22 of 31; Schedule 4/2, 16 of 22), as evidenced by a decline in maximum standardized uptake volume (SUV max ) of ≥25% relative to baseline (as defined by the European Organization for Research and Treatment of Cancer; ref. 26 ) and visualized as a marked decline in FDG avidity (Fig. 1A and B) . With temporary cessation of sunitinib dosing during the first cycle, many patients whose tumors had shown decreased FDG avidity exhibited a rebound of metabolic activity followed by another decline in tracer uptake when dosing resumed (Fig. 1C  and D) . Early changes in tumor metabolism correlated with improved clinical outcome: most of the 43 patients with PMRs subsequently showed clinical benefit based on CT or magnetic resonance imaging scans, with 6 PRs and 25 SD ≥6 months by February 2005. PK analysis. Steady-state conditions were achieved by days 7 to 10 for sunitinib and by days 7 to 21 for SU12662 across all dosing schedules. At 50 mg/d, 79% of PK-evaluable patients (38 of 48) achieved total drug (sunitinib + SU12662) trough concentrations above 50 ng/mL by day 14, with 33% (13 of 40) achieving this within the first 7 days. Median trough concentrations of total drug at 50 mg/d were in the range of 48 to 63 ng/mL on Schedule 2/1, 32 to 47 ng/mL on Schedule 2/2, and 38 to 66 ng/mL on Schedule 4/2 over the remainder of the dosing period (day 7 to days 14 or 28).
Increasing exposure seemed to correlate with increased DLTs. At 75 mg/d on day 14, the median total drug trough concentration was 93.4 ng/mL, with the two patients who experienced DLTs having concentrations of 107 and 102 ng/mL. One patient who experienced a DLT (diarrhea) at 50 mg/d had a trough concentration of 84.0 ng/mL on day 14.
Cellular and molecular analyses of GIST lesions. Forty-eight patients (49%) had matched baseline (post-imatinib, presunitinib) and post-sunitinib biopsies. In 11 additional patients, either the pre-or post-sunitinib biopsy contained no demonstrable tumor.
Before sunitinib dosing, the biopsies showed KIT expression in 43 cases (90%; example shown in Fig. 2 ), whereas 5 cases were KIT negative; 4 of the latter cases had very limited biopsy material, raising the possibility of sampling error. Three postsunitinib biopsies were KIT negative, although the corresponding pre-sunitinib biopsies had been KIT positive. However, in the majority of tumors, changes in KIT expression (if any) were subtle (Fig. 2) .
Tumor cell proliferation, assessed by MIB-1 antibody detection of Ki67, was reduced by >25% in 25 cases (52%) after 1 week of sunitinib treatment (example shown in Fig. 3 ). In 13 cases (27%), the MIB-1 score was relatively unchanged; in 10 cases (21%), it increased by >25%.
Sufficient material for immunoblotting assays was obtained from 28 patients with matched pre-and post-sunitinib biopsies. Nine of these matched sets showed reduced levels of phospho-KIT after 1 week of sunitinib treatment accompanied by changes in the phosphorylation or expression of proteins involved in cell proliferation (AKT, cyclin A, and p27) that were consistent with growth inhibition (examples shown in Fig. 4) . Eight patients had matched biopsy sets with no evidence of response by immunoblotting, and biopsies from 11 patients were inevaluable because either the pre-or postsunitinib biopsy was judged to represent residual tumor with few viable GIST cells. Of the two patients for whom immunoblotting results are shown in Fig. 4A , patient 14 had a primary KIT exon 9 mutation without detectable secondary mutations at the time of study entry and achieved an objective PR. In patient 2, in addition to a primary KIT exon 11 V560D mutation, a supraclavicular metastasis had a secondary exon 13 V654A imatinib resistance mutation (which involves the kinase ATP-binding pocket), whereas a hepatic metastasis had a different imatinib resistance mutation (exon 17 D816H) involving the activation loop domain. This patient had SD as best response, but the hepatic metastasis progressed within 4 months, whereas the supraclavicular GIST lesion continued to be well controlled on sunitinib.
Safety. DLTs (predominantly nausea, fatigue, and vomiting) were documented primarily at the 75-mg sunitinib dose level; otherwise, treatment-related adverse events were generally mild to moderate in severity, the most common of which were fatigue, diarrhea, and nausea (Table 2) . Grade 3 or 4 increases in lipase occurred in 13% of patients; these events were generally asymptomatic, although one patient experienced clinical symptoms of pancreatitis. Thirty-seven percent of patients experienced hand-foot syndrome.
Cardiovascular events included hypertension (>150/100 mmHg per National Cancer Institute Common Toxicity Criteria version 2.0), which was detected in 52% of patients and reported as a treatment-related adverse event in 29%, and left ventricular ejection fraction below the lower limit of normal (as measured using multigated acquisition scans) in 14% of patients. Left ventricular ejection fraction declines were generally reversible with medical management; however, some patients showed transient elevations in serum TnI levels, generally without symptoms. Two patients developed signs or symptoms of myocardial infarction (electrocardiogram changes with new Q waves and/or TnI elevation with accompanying chest pain or ischemic ST-T wave changes). Hypothyroidism was reported as a treatment-related adverse event in a subset of patients (18%) with prolonged sunitinib dosing and was managed with thyroid hormone replacement therapy.
Eleven patients died within 30 days of their last sunitinib dose, and 1 patient died afterwards on follow-up; none of these events were considered to be treatment related.
Discussion
This study shows that sunitinib has biological and clinical activity across multiple dosing schedules in GIST patients after imatinib failure. Without exception, the patients in this trial had advanced metastases with bulky disease progressing at the time of study entry. Although only a small subset exhibited tumor shrinkage after initiation of sunitinib treatment, 54% ultimately received clinical benefit (objective response or durable SD). In the majority of patients, reduced tumor glycolytic activity was evident on FDG-PET imaging within 1 week of starting sunitinib. Overall, 43 of 60 patients (72%) who had FDG-PET imaging on day 7 of cycle 1 (when concentrations of sunitinib and its metabolite were approaching steady state) achieved PMRs, with reductions in tumor SUV max of ≥25% relative to baseline. As defined in European Organization for Research and Treatment of Cancer guidelines in 1999 (26), acceptable SUV max cutoffs for PMRs in the first cycle of treatment range from 15% to 25%, with the latter value being the currently recognized standard. In contrast to PMRs, objective responses on CT took much longer to detect and evolved over several months, similar to the pattern observed in studies of imatinib-treated GIST patients (5, 6, 27) . Moreover, early PMRs correlated with improved clinical outcome: 31 of the 43 patients with PMRs experienced clinical benefit as determined subsequently by CT. This is also similar to what has been reported in studies of first-line treatment with imatinib, in which early metabolic responses have been found to correlate with subsequent anatomic responses (5, 27) .
KIT expression in most GISTs analyzed (94%) was unaffected after 10 days of sunitinib therapy. Nevertheless, in 32% of cases analyzed, levels of phospho-KIT were reduced after 1 week of sunitinib treatment, indicating effective target modulation. Moreover, these changes were accompanied by changes in the activity or expression of proteins involved in cell proliferation (AKT, cyclin A, and p27) consistent with growth inhibition. These results correlated both with previous preclinical observations (11) and with the observation that, after 1 week of sunitinib therapy, tumor cell proliferation was reduced by >25% in 52% of cases. They also correlated with clinical outcome in several cases, such as the two cases presented in Fig. 4 , although correlations between KIT signaling pathway changes and clinical outcome were not formally assessed. Taken together, the results suggest that sunitinib clinical activity may be associated with inhibition of KIT kinase activity, although a direct causal link remains to be established.
Results of this study showed that as early as day 7, steadystate conditions of sunitinib and active metabolite SU12662 were achieved across all dosing schedules. By day 14, 79% of patients on 50 mg/d had achieved total drug trough concentrations above 50 ng/mL, the concentration providing target RTK inhibition in preclinical studies (12) . Dose responses were observed in terms of both efficacy and safety.
Overall, sunitinib treatment was associated with acceptable safety in these patients with advanced metastatic GIST. In most patients, adverse events were mild to moderate in severity, most commonly constitutional symptoms such as nausea, vomiting, diarrhea, and fatigue or skin toxicities such as skin discoloration and hand-foot syndrome. DLTs (fatigue, nausea, and vomiting) were seen primarily at 75 mg/d, leading to selection of 50 mg/d as the recommended phase II dose, consistent with other sunitinib dose-finding studies (28, 29) . Schedule 4/2 was selected for further phase II evaluation to maximize duration of sunitinib exposure following evidence of promising clinical activity with acceptable safety.
Hypertension, known to be a class effect of angiogenesis inhibitors (30) , was detected in 52% of patients and was managed with conventional antihypertensive medications. Decreased cardiac function, when observed, generally reversed after sunitinib discontinuation or dose reduction, along with addition of agents such as angiotensin-converting enzyme inhibitors, β-blocking agents, and/or diuretics. Cardiovascular toxicities that occurred among the 75 patients at one of the participating institutions in this study have been examined in more detail and reported elsewhere (31) .
Hypothyroidism, reported as a treatment-related adverse event in 18% of patients in this study, is now known to be associated with long-term sunitinib therapy (19, 32) and is manageable through thyroid hormone replacement therapy. The mechanism has yet to be determined, although inhibition of iodine uptake, peroxidase activity, and VEGFR within the thyroid are among several that have been proposed (32) (33) (34) .
In conclusion, inhibition of multiple RTKs with sunitinib in GIST patients following imatinib failure was achieved with acceptable safety and promising evidence of antitumor activity. Based on the results of this study, a randomized, double-blind, placebo-controlled phase III study was conducted to evaluate the efficacy of sunitinib (50 mg/d, Schedule 4/2) in imatinibresistant/intolerant GIST patients, and the interim results were positive (18) , resulting in multinational approval of sunitinib for the treatment of this patient population (19) . Additional research is needed to elucidate the specific mechanisms underlying the activity of sunitinib; it is unclear whether sunitinib inhibits different conformations of mutant KIT or PDGFRA more potently than imatinib or whether inhibition of other RTKs, such as the VEGFRs, accounts for this activity in imatinib-resistant GIST. Further research on the effects of primary and secondary tumor kinase mutations on GIST response to sunitinib may provide important insights on which to improve the clinical outcomes of GIST patients after imatinib failure as well as other kinase-driven malignancies. 
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